 Home > Active Ingredient News > Antitumor Therapy > Roche's PD-1/LAG-3 bispecific antibody has been declared for clinical use in China, and is expected to be used for the treatment of metastatic melanoma, non-small cell lung cancer, esophageal squamous cell carcinoma, and advanced liver cancer.

Roche's PD-1/LAG-3 bispecific antibody has been declared for clinical use in China, and is expected to be used for the treatment of metastatic melanoma, non-small cell lung cancer, esophageal squamous cell carcinoma, and advanced liver cancer.

 Last Update: 2021-08-01
 Source: Internet
 Author: User

Tags

adenovirus gene therapy

1 3 dilution

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Chinese State Drug Administration Bureau Center for Drug Evaluation (CDE) public display, Roche (Roche) under development RO7247669 injection has been declared clinically in China, and on July 2 were entertained
.

Public information shows that RO7247669 is a bispecific antibody targeting PD-1 and LAG-3 , and Phase 1/2 clinical trials are being carried out worldwide

Management RO7247669 is a bispecific antibody targeting PD-1 and LAG-3

Bispecific antibody is an antibody that can specifically bind to two different antigens
.

This type of therapy uses T cells in the patient’s immune system to kill tumors.

immunity

RO7247669 is a bispecific antibody targeting PD-1 and LAG-3 developed by Roche
.

The PD-1/PD-L1 immune checkpoint is a star target in the field of cancer immunotherapy and is well known to everyone

LAG-3 is called lymphocyte activation gene-3.
It is an immune checkpoint protein expressed on the surface of effector T cells and regulatory T cells (Tregs), which can regulate the signals of T lymphocytes and antigen presenting cells (APCs).
The pathway plays an important role in the adaptive immune response
.

LAG-3 and PD-1 mediate different signaling pathways, but they may have a synergistic effect, leading to depletion of effector T cells

Clinicaltrials.
gov website publicity information display, Roche is carrying out clinical trials to assess the safety and efficacy of RO7247669 indications covered include metastatic melanoma, non-small cell lung cancer, esophageal squamous cell carcinoma, advanced liver cancer and so on
.

According to the information on the CDE website, this is the first clinical application for RO7247669 in China

Metastatic melanoma, non-small cell lung cancer, esophageal squamous cell carcinoma, advanced liver cancer in this message

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.